An observational study in Pelvic Fracture, sponsored by AO Innovation Translation Center. Active, not recruiting at 10 sites in 7 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by AO Innovation Translation Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Hip Fractures with a site in Germany — 1 open to participants now, 9 under way, none of them phase 3. Hip Fractures · Germany.
Among the 25 studies in Hip Fractures with a site in Germany, this one is the only one that started in 2022, is one of 9 observational ones, and was the 18th registered.
843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.
Browse Hip Fractures studies →1 of the 25 studies in Hip Fractures with a site in Germany is open now. Recruiting first, the newest first:
AgNovos Healthcare, LLC · Sites in Germany, Austria, Belgium and 8 more countries
Ages 65–91 · Women only
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 420 is above the median of 149 across 280 observational studies indexed under Hip Fractures.
Median enrollment 251 across the 16 interventional studies, 125 across the 9 observational. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 25 have an industry lead sponsor. The 10 most frequent:
AO Innovation Translation Center is the lead sponsor of 32 studies on the registry; 11 are open to participants now.
AO Innovation Translation Center has 7 studies filed under Hip Fractures — fewer than ten, so there is no comparison to draw.
4 of the studies in Hip Fractures with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04113044AO Innovation Translation CenterGo Fit Fast, Recovery Trajectory Using PROMIS®, Linking PROMIS® | 2026-12-31 |
| NCT04796350AgNovos Healthcare, LLCRESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures | 2027-04-01 |
| NCT05367505University of Witten/HerdeckeTitanium Fusion Implant in Combination With Trans-iliac Screws for Insufficiency Fractures of the Pelvis | 2027-06-07 |
| NCT04182776AO Innovation Translation CenterFragility Fractures of the Pelvis (FFP) | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 25 studies in Hip Fractures with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Prospective data will be collected in approximately 420 patients, above the age of 65, suffering from an FFP type fracture equal to or higher than type II, according to Rommens and Hofmann.
Patients will be followed up according to the standard (routine) for up to 1 year after the treatment. Data collection will include underlying disease, treatment details, functional and patient reported outcomes (PRO)s, radiological outcomes, and anticipated or procedure-related adverse events (i.e. complications).
More in detail this registry has the following objectives:
Elderly patients (over 65) who have suffered from fragility fractures of the pelvis (FFP), equal to or higher than type II (according to Rommens and Hofmann)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
obtained, ie:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics. The registry does not dictate any specific treatment.
Demographics
Year of birth, Gender, Ethnicity, Height (cm) and Weight (kg) will be combined to report BMI in kg/m\^2
Time frame: Pre-treatment
Comorbidities
Concomitant diseases will be assessed using the Charlson Comorbidity Index (CCI). This score assesses the comorbidity level by considering both the number and severity of pre-defined comorbid conditions. It provides a weighted score of a patient's comorbidities which can be used to predict mortality rates. It is a 17-items questionnaire with score range from 0 to 37 points. It estimates the 10-year (or shorter) patient survival.
Time frame: Pre-treatment
Cognitive status
The MiniCog is a 3-minute instrument assessing cognitive impairment. It consists of two components, a 3-item recall test for memory and a simply scored clock drawing test. A total score ranges from 0 to 5. A score of zero, one or two out of five points in total, indicates a concern in cognitive functioning.
Time frame: Pre-treatment
Patient-reported outcomes: PROMIS Pain Interference
PROMIS (Patient-Reported Outcome Measurement Information System) Pain Interference (8 questions) assesses the impact of pain on common activities of daily life including social, cognitive, emotional, physical, and recreational aspects. The higher score represents a higher pain level.
Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)
Patient-reported outcomes: PROMIS Physical Function
PROMIS Physical Function (10 questions) assesses self-reported capability of physical activities including instrumental activities of daily living. A higher score indicates a better self-reported capability.
Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)
Patient Reported Outcomes - EuroQoL (EQ-5D-3L)
The EQ-5D-3L has five items (mobility, self-care, usual activities, pain/discomfort anxiety/depression) with a three-point categorical response scale level (1 = no problems, 2 = some / moderate problems, 3 = extreme problems) where the patient's current health status is assessed. A unique EQ-5D-3L health state is defined by combining one level from each of the five dimensions. The EQ-5D index score ranges from 0 (death) to 1 (best imaginable quality of life), and negative values express "worse than death" state.
Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)
Parker Mobility Score
Parker Mobility Scale assess the patient's ability to perform indoor walking, outdoor walking, and shopping before the fracture. A score ranges between 0 and 3 (0 = not at all, 1 = with help from another person, 2 = with an aid, and 3 = no difficulty and no aid) for each function, resulting in a total score ranging from 0 (no walking ability at all) to 9 (fully independent).
Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)
Modified Barthel index
The Barthel index is an ordinal scale and each performance item is rated on this scale with a given number of points assigned to each level or ranking. It uses 10 variables describing activities of daily living and mobility. A higher number is associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital.
Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)
Residential status
The residential status will be documented at each visit during 1-year post-treatment phase.
Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)
Mortality
Mortality will be assessed for 4 phases: * Perioperative mortality * Within the first 7 days after treatment (early-term) * Within the first 3 months after treatment (mid-term) * Until the last follow up (long-term mortality)
Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)
Radiological outcomes
Position of the fracture fragments, to rule out secondary (additional) fracture fragments and displacement, or loosening of implants (Undisplaced, Displaced, Non-union with extensive callus)
Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)
Anticipated treatment or condition-related adverse events (i.e. complications)
In this registry, only condition- or treatment-related events (ie complications) will be collected . Partially those events presuppose themselves: eg, re-admission for a surgical revision. In those cases, details on those different events will be collected.
Time frame: from the pre-treatment assessment until 12 months after the treatment (surgical or not-surgical)
Started Mar 2022 (actual). Primary completion is estimated for Jul 2027, 64 months after the start.
Of 107 non-industry observational studies under Hip Fractures, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 65. This study's planned 64 months is above that.
Counting every sponsor, half of 124 studies reached it within 28 months; a quarter within 12 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AO Innovation Translation Center